Better Health for All

Erasca's primary focus is developing therapies for RAS/MAPK pathway-driven cancers, which aligns with the goal of improving health outcomes

, . The company's pipeline includes multiple therapies in clinical trials, such as naporafenib, ERAS-0015, and ERAS-4001 . Naporafenib has received FDA Fast Track Designation, indicating its potential to address an unmet medical need in advanced NRAS-mutated melanoma . Erasca intends to make clinical trials more accessible to diverse patient populations . The Erasca Foundation, funded by 1% of the company's IPO capital, supports cancer research and patient advocacy . However, there is no available data on pricing, accessibility, or specific risk/benefit information for each therapy , , . The company emphasizes safety and efficacy in clinical trials . The company's San Diego office has Gold LEED certification, and its San Francisco office has Platinum LEED certification . Given the focus on cancer therapies and the early stage of development, a score of +20 is appropriate. The company is investing in health innovation, but accessibility and impact remain to be seen.

Fair Money & Economic Opportunity

Erasca, Inc. is a biopharmaceutical company, and its core business does not involve lending, insurance, or other financial services to consumers. Therefore, KPIs related to financial products, pricing, fees, lending compliance, debt burden, and customer wealth building are not applicable. The company does not generate or manage customer financial data in the context of banking or lending, nor does it operate financial service access points. While Erasca has established the Erasca Foundation, which provides grants and supports patient education and access to clinical trials for underserved populations, these activities do not fall under the scope of financial services as defined by the rubric's KPIs.

The company made a $125,000 donation to the Erasca Foundation in April 2024, and the foundation was initially funded by a donation of 1% of Erasca's capital stock at the time of its IPO. However, without the company's annual pre-tax profit, the percentage of profit reinvested cannot be calculated for the 'profit_reinvestment' KPI. The Erasca Foundation provides patient education, but the extent and impact of these programs are not quantified to meet the 'financial_literacy_initiatives' KPI.

Kind to Animals

The company conducts animal testing for its drug development.

Preclinical studies for ERAS-0015 and ERAS-4001 involve in vivo testing in multiple animal species to assess potency, absorption, distribution, metabolism, excretion (ADME), pharmacokinetic (PK) properties, and tumor regression. While in vitro testing is also mentioned, the extensive use of in vivo methods for critical drug development endpoints suggests a primary reliance on animal tests. A job posting for a Vivarium Technician further confirms the company's engagement in animal studies and adherence to IACUC protocols. No explicit animal testing policy is mentioned in the provided articles, indicating a lack of transparency or formal commitment regarding animal welfare in testing beyond regulatory compliance.

No War, No Weapons

No specific, concrete evidence was found in the provided articles to assess Erasca, Inc. against any of the KPIs for the 'No War, No Weapons' ethical value. The articles describe the company's corporate governance and code of conduct, including an obligation to comply with laws covering sanctioned countries and U.S. export control laws, and a policy regarding employee social media use for political lobbying.

However, these statements do not provide quantifiable data or specific actions related to arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other relevant metrics required by the rubric.

Planet-Friendly Business

Erasca's San Diego office is Gold Level Leadership in Energy and Environmental Design (LEED) certified, and its San Francisco office is Platinum Level LEED certified.

The company also encourages employees to recycle, including specific programs for certain lab supplies. Its chemists are committed to increasing efficiencies, reducing materials, and minimizing waste in the manufacturing process, which is conducted by third-party vendors. Additionally, the company's offices are accessible by public transportation and feature electric vehicle charging stations and indoor bike racks. Erasca has adopted virtual annual meetings and online proxy materials to reduce environmental impact and costs.

Respect for Cultures & Communities

No specific, concrete data points were found in the provided articles to assess Erasca, Inc. against the defined KPIs for 'Respect for Cultures & Communities'. While the company made a $125,000 donation to the Erasca Foundation in April 2024, and the Foundation was funded by 1% of Erasca, Inc.'s capital stock at IPO, the articles do not provide the company's total revenue or the percentage of revenue reinvested in local community development.

Similarly, there is no information on the number of formal partnership agreements with indigenous or local community groups, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, or other specific metrics required by the rubric.

Safe & Smart Tech

Erasca, Inc. demonstrates good compliance with applicable regulations, including US GAAP, SEC regulations, cGMP, GCP, GLP, Export Control Laws, and various data protection and privacy laws.

For EU residents, the company states it will take appropriate steps to ensure transferred personal information remains protected and secure, including using Standard Contractual Clauses. Users are provided with excellent control over their personal data, including rights to object, request restriction, access, rectification, erasure, and portability of information, as well as options to opt-out of communications and request removal or correction of data. The company uses the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF) for identifying, assessing, and mitigating cybersecurity risks. Its Audit Committee oversees cybersecurity risks, receiving reports from management at least twice per year, and the full Board receives briefings. The IT security team responsible for managing cybersecurity risks has over 50 years of experience. Erasca states it uses industry-standard security technologies and procedures to protect personal information and may use a third party to gather information about website usage. The company's privacy policy, effective June 1, 2021, describes the types of personal information collected and how it is used.

Zero Waste & Sustainable Products

The company has implemented several waste reduction initiatives, including recycling programs for certain lab supplies and a commitment from chemists to increase efficiencies, reduce materials, and minimize waste in the manufacturing process.

Additionally, the company reduces environmental impact by providing proxy materials to stockholders online instead of mailing printed copies. No waste disposal violations or citations have been mentioned in the provided articles.